Additionally, the inhibition of TGM2 in cell lines has demonstrated therapeutic potential, further supporting its role as a target for overcoming resistance in CRC,60 with compounds such as levamisole representing potential candidates for targeting its activity. The gene discussed is TGM2; the disease is colorectal carcinoma.